Phosphodiesterase Families

Handbook of Cell Signaling, Second Edition

Volumn 2, Issue , 2009, Pages 1409-1414

  Surapisitchat, James ^a   Beavo, Joseph A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955889450     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374145-5.00173-X     Document Type: Chapter

References (43)

1. JA Beavo and LL Brunton (2002) Cyclic nucleotide research – still expanding after half a century. Nat Rev 3 710-718.
2. WY Cheung (1970) Cyclic nucleotide phosphodiesterase. Adv Biochem Psychopharmacol 3 51-65.
3. JA Beavo (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Revi 75 725-748.
4. AR Redman and GJ Ryan (2001) Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke. Clin Ther 23 1391-1408.
5. MD Houslay (2001) PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biology 69 249-315.
6. SH Soderling and JA Beavo (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12 174-179.
7. H Charbonneau, N Beier, KA Walsh and JA Beavo (1986) Identification of a conserved domain among cyclic nucleotide phosphodiesterases from diverse species. Proc Natl Acad Sci USA 83 9308-9312.
8. TJ Martins, MC Mumby and JA Beavo (1982) Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem 257 1973-1979.
9. SH Soderling, SJ Bayuga and JA Beavo (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 96 7071-7076.
10. J Surapisitchat, KI Jeon, C Yan and JA Beavo (2007) Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ Res 101 811-818.
11. R Kakkar, RV Raju and RK Sharma (1999) Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell Mol Life Sci 55 1164-1186.
12. L Aravind and CP Ponting (1997) The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci 22 458-459.
13. BL Taylor and IB Zhulin (1999) PAS domains: internal sensors of oxygen, redox potential, and light. Microbiol Mol Biol Rev 63 479-506.
14. AZ Zhao, KE Bornfeldt and JA Beavo (1998) Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest 102 869-873.
15. C Yan, JK Bentley, WK Sonnenburg and JA Beavo (1994) Differential expression of the 61-kDa and 63-kDa calmodulin-dependent phosphodiesterases in the mouse brain. J Neurosci 14 973-984.
16. JA Beavo, JG Hardman and EW Sutherland (1971) Stimulation of adenosine 3′,5′-monophosphate hydrolysis by guanosine 3′,5′-monophosphate. J Biol Chem 246 3841-3846.
17. DM Juilfs, HJ Fulle, AZ Zhao, MD Houslay, DL Garbers and JA Beavo (1997) A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. Proc Natl Acad Sci USA 94 3388-3395.
18. R Fischmeister, LR Castro, A Abi-Gerges, et al. (2006) Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99 816-828.
19. G Vandecasteele, I Verde, C Rucker-Martin, P Donzeau-Gouge and R Fischmeister (2001) Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes. J Physiol 533 329-340.
20. IL Buxton and LL Brunton (1983) Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem 258 10,233-10,239.
21. JS Hayes, LL Brunton and SE Mayer (1980) Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E1. J Biol Chem 255 5113-5119.
22. TJ Kelley, K Thomas, LJ Milgram and ML Drumm (1997) In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium. Proc Natl Acad Sci USA 94 2604-2608.
23. D Kim, SD Rybalkin, X Pi, et al. (2001) Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104 2338-2343.
24. SD Rybalkin, KE Bornfeldt, WK Sonnenburg, et al. (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 100 2611-2621.
25. L Li, C Yee and JA Beavo (1999) CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283 848-851.
26. AT Bender, CL Ostenson, EH Wang and JA Beavo (2005) Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation. Proc Natl Acad Sci USA 102 497-502.
27. D Kim, T Aizawa, H Wei, et al. (2005) Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol 38 175-184.
28. J Nagendran, SL Archer, D Soliman, et al. (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116 238-248.
29. B Ding, J Abe, H Wei, et al. (2005) Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111 2469-2476.
30. T Rahn Landstrom, J Mei, M Karlsson, V Manganiello and E Degerman (2000) Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP. Biochem J 346 337-343.
31. J Seybold, D Thomas, M Witzenrath, et al. (2005) Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 105 3569-3576.
32. C Kroegel and M Foerster (2007) Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast. Expert Opin Invest Drugs 16 109-124.
33. SN Smith, PG Middleton, S Chadwick, et al. (1999) The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Am J Respir Cell Mol Biol 20 129-134.
34. RT Eberhardt and JD Coffman (2000) Drug treatment of peripheral vascular disease. Heart Dis (Hagerstown) 2 62-74.
35. C El-Beyrouty and SA Spinler (2001) Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. Ann Pharmacother 35 1108-1113.
36. CR Gibbs and GY Lip (1998) Do we still need dipyridamole? Br J Clin Pharmacol 45 323-328.
37. C Sudlow (2007) Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA. Br Med J (Clin Res ed) 334 901.
38. N Galie, HA Ghofrani, A Torbicki, et al. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 2148-2157.
39. E Takimoto, HC Champion, M Li, et al. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature Med 11 214-222.
40. PV Agostino, SA Plano and DA Golombek (2007) Sildenafil accelerates reentrainment of circadian rhythms after advancing light schedules. Proc Natl Acad Sci USA 104 9834-9839.
41. SH Soderling, SJ Bayuga and JA Beavo (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 95 8991-8996.
42. V Vasta, M Shimizu-Albergine and JA Beavo (2006) Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A. Proc Natl Acad Sci USA 103 19,925-19,930.
43. A Dov, E Abramovitch, N Warwar and R Nesher (2007) Diminished PDE8B potentiates biphasic insulin response to glucose. Endocrinology 149 741-748.